Chung Hyung-min explained

Chung Hyung-min
Birth Place:South Korea
Nationality:South Korean
Field:Stem cell research
Work Institution:CHA Stem Cell Institute, CHA University
Alma Mater:Konkuk University
Doctoral Advisor:Chung Kil-saeng
Known For:Animal Biotechnology & Stem cell research
Prizes:2004: Society for Assisted Reproductive Technology (SART) Prize Paper
2009: "CEO of Next generation" (for Bio Technology), Ministry of Knowledge Economy

Chung Hyung-min is a South Korean biotechnology professor.[1] [2] [3] He was appointed professor at CHA University in 1997 after obtaining his BA, MA and Ph.D degree at Konkuk University.

Currently, he is a professor of biomedical science at CHA University, Director of CHA Stemcell Institute, President of CHA Bio & Diostech Inc., Member of LMO Assessment Advisory Committee for Ministry of Health and Welfare, and Advisor for the Ministry of Knowledge Economy under the National Technical Advisory Committee. Dr Chung is a prominent leader in the field of stem cell research with over 20 years of experience.

His research aims at the development of stem cell therapies using human adult and embryonic stem cells. Primarily, his study focusses on the clinical applications of human embryonic stem cell-derived retinal cells, artificial blood and cardiovascular cells.

His research group became only the second in the world to be approvedto conduct clinical application of human embryonic stem cells for the treatment of an orphan disease named Stargardt's macular dystrophy.

Education

Awards

Publications

  1. 21235296. 2011. Lee. MJ. Kim. J. Lee. KI. Shin. JM. Chae. JI. Chung. HM. Enhancement of wound healing by secretory factors of endothelial precursor cells derived from human embryonic stem cells. 13. 2. 165–78. 10.3109/14653249.2010.512632. Cytotherapy.
  2. 21126165. 2011. Kim. MJ. Park. JS. Kim. S. Moon. SH. Yang. HN. Park. KH. Chung. HM. Encapsulation of bone morphogenic protein-2 with Cbfa1-overexpressing osteogenic cells derived from human embryonic stem cells in hydrogel accelerates bone tissue regeneration. 20. 8. 1349–58. 10.1089/scd.2010.0311. Stem Cells and Development.
  3. 20958217. 2010. Kim. EY. Jeon. K. Park. HY. Han. YJ. Yang. BC. Park. SB. Chung. HM. Park. SP. Differences between cellular and molecular profiles of induced pluripotent stem cells generated from mouse embryonic fibroblasts. 12. 6. 627–39. 10.1089/cell.2010.0013. 2998986. Cellular Reprogramming.
  4. 20920899. 2011. Moon. SH. Kim. JS. Park. SJ. Lim. JJ. Lee. HJ. Lee. SM. Chung. HM. Effect of chromosome instability on the maintenance and differentiation of human embryonic stem cells in vitro and in vivo. 6. 1. 50–9. 10.1016/j.scr.2010.08.006. Stem Cell Research.
  5. 20884805. 2010. Park. SW. Jun Koh. Y. Jeon. J. Cho. YH. Jang. MJ. Kang. Y. Kim. MJ. Choi. C. Sook Cho. Y. 8. Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways. 116. 25. 5762–72. 10.1182/blood-2010-04-280719. Blood. free.

External links

Notes and References

  1. News: Stem cells bring life to biotech industry. JoongAng Ilbo. 2012-01-25. 2014-07-12.
  2. News: Bioethics body approves first embryonic stem cell test. The Korea Herald. 2011-04-27. 2014-07-12.
  3. News: South Korea to Lift Ban On Human Stem Cell Research. U.S. News & World Report. 2009-04-29. 2014-07-12.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Chung Hyung-min".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.